LC-ESI-MS/MSを用いた新生児期から青年でのウルソデオキシコール酸の代謝物硫酸抱合型とN-アセチルグルコサミン抱合型の分析 by 武井 一
1  
 
Transition of urinary ursodeoxycholic acid 7β-N- 
acetylglucosaminide and 3α-sulfate from neonates to adolescents 
using LC-ESI-MS/MS analysis 
 
Hajime Takeia,b, Tsuyoshi Muraic, Takao Kurosawac, Takashi Iidad, Hiroshi 
Nittonoa,b, Masaya Fujishirob, Xiao-Pen Leeb, Junichi Satob, Keizo Satob 
 
 
aJunshin Clinic Bile Acid Institute, Haramachi, Meguro-ku, Tokyo 152-0011, 
 
Japan 
 
bDepartment of Legal Medicine, Showa University School of Medicine. 
cSchool of Pharmacetical Science, Health Science University of Hokkaido. 
dDepartment of Chemistry, Colleage of Humanities & Science, Nihon 
University. 
 
 
Running title: 
 
Urinary UDCA-7β-NAG & 3α-sulfate by LC-ESI-MS/MS 
2  
 
Abstract 
 
This study evaluated the urinary metabolism of ursodeoxycholic acid 
(UDCA) by measuring 7β-N-acetylglucosaminide and 3α-sulfate 
composition in neonates to adolescents using liquid chromatography 
electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). We 
obtained urine from 13 babies, corrected gestational age (CGA) 37-70 weeks, 
receiving UDCA to treat cholestasis due to total parenteral nutrition (TPN) 
and 8 patients, aged from 9 months to 15 years, who were treated with oral 
UDCA administration. The ratios of each UDCA conjugate to total UDCA 
were as follows: at CGA 37-42 weeks: non-amidated and glycine- or taurine- 
amidated  ursodeoxycholic  acid  (UDCAs):  44.0 ± 8.0%  (mean ± SD), 
 
UDCAs    3α-sulfate    (UDCAs-3S):    37.8    ±    10.1%,    UDCAs  7β-N- 
 
acetylglucosaminide (UDCAs-7NAG): 18.1 ± 14.9%; at 9months-3years: 
UDCAs: 15.7 ± 23.2%, UDCAs-3S: 37.2 ± 8.8%, UDCAs-7NAG: 47.0    ± 
22.1%. The ratios of UDCAs-3S and UDCAs-7NAG increased gradually 
between the ages of 5 and 15 years, as follows: UDCAs, 2.2 ± 1.3%; 
UDCAs-3S, 51.2 ± 22.9%; and, UDCAs-7NAG, 46.6 ± 22.6%. The ratio of 
3-sulfooxy-7-N-acetylglucosaminyl-UDCAs (UDCAs-3S-7NAG) lowered 
by 0.2% per each age group. Urinary UDCAs-7NAG was not detectable in 
2 of 21 patients, who were thus considered to have 7β-hydroxy bile acid N- 
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acetylglucosaminyl transferase (UGT3A1) deficiency. The enzyme activity 
of N-acetylglucosaminyl transferase to UDCAs was at the same degree as 
sulfotransferase to UDCAs in early neonates, but reached the adult values by 
3-5 years. 
 
 
Key words: ursodeoxycholic acid, 7β-N-acetylglucosaminide, 3α-sulfate, 
liquid chromatography-tandem mass spectrometry 
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Introduction 
 
Bile acids (BAs) are synthesized from cholesterol through various 
enzymatic reactions in the liver. Before being excreted into canaliculi, 
primary BAs, cholic acid (CA) and chenodeoxycholic acid (CDCA), are 
conjugated predominantly with taurine or glycine amino acids at the 
position-24 carboxylic group of BAs. After secretion into the small intestine 
through the bile duct, secondary BAs, deoxycholic acid (DCA), lithocholic 
acid (LCA), and UDCA, are converted from the primary BAs by the action 
of intestinal microbiota. Most primary and secondary BAs are reabsorbed 
back to the liver via the portal circulation for re-secretion into bile via a 
process called enterohepatic circulation [1]. 
BAs consist of free BAs and their conjugated forms, with two amino 
acids (glycine and taurine), sulfonic acid, glucoside, glucuronic acid, and N- 
acetylglucosamine [2-5]. The compositions of these BAs and their 
conjugated forms can differ significantly at different periods of life from 
neonates to adults and also between healthy humans and patients with 
disorders such as liver disease. In patients with severe cholestasis for 
example, BAs are excreted into the urine In patients with severe cholestasis 
for example, BAs are more likely excreted into the urine as their sulfate 
conjugation (forms mostly at C-3) and increases BA their hydrophilicity. [6- 
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8]. In lower amounts, BAs are also glucuronidated at C-3 or C24. N- 
acetylglucosaminidation is seemingly an even more selective glycosidic 
conjugation reaction because only 7β-hydroxylated BAs seem to be 
conjugated with N-acetylglucosamine in adult patients treated with UDCA 
[9-10], and the 7β-N-acetylglucosaminyl-UDCA glycine conjugate 
(GUDCA-7NAG) is part of the main pathway for excretion into urine 
together with 3α-sulfooxy-UDCA (UDCA-3S) glycine conjugates in adults. 
The safe and efficient drug metabolism and excretion system are established 
dramatically through neonatal, infant, child, and adolescent periods [11]. 
During infancy, these changes are dynamic and largely related to organ 
functions important in metabolism, excretion, and changes in body 
composition; however, because changes in UDCA metabolism and the 
resultant metabolites are not known during infancy, we aimed to evaluate the 
UDCA metabolites, UDCAs-7NAG and UDCAs-3S, in urine. 
Reported methods for UDCAs-7NAG analysis in the urine of primary 
biliary cirrhosis (PBC) adult patients with UDCA treatment include fast atom 
bombardment mass spectrometry (FAB-MS) [12], high performance liquid 
chromatography (HPLC) [10], and enzyme-linked immunosorbent assay 
(ELISA) [13]. In contrast, LC-ESI-MS/MS has been used for the analysis of 
UDCAs-3S [14,15], but not for UDCAs-7NAG analysis. This study sought 
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to establish a highly sensitive measurement of urinary UDCAs-7NAG using 
LC-ESI-MS/MS, including its application to clinical samples, especially in 
low birth weight (LBW) neonates requiring the administration of UDCA for 
cholestasis induced by TPN (Total Parenteral Nutrition). Using the method, 
we found that neonates mainly excrete glycoursodeoxycholic acid 
(GUDCA) and tauroursodeoxycholic acid (TUDCA) and considerable 
amounts of both UDCAs-3S and UDCAs-7NAG. The urinary UDCAs-3S 
and UDCAs-7NAG levels gradually increased with age, and the urinary 
levels of 3 to 5-year olds were close to that of adolescents being administered 
exogenous UDCA. 
 
 
Materials and methods 
Chemicals and reagents 
Authentic reference bile acids used in this study were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) as follows: CA, CDCA, UDCA, DCA, 
LCA, and d4-CA (as an internal reference standard for LC-ESI-MS/MS 
analysis). Glycine- and taurine-conjugated bile acids were also purchased 
from Sigma-Aldrich. Other internal reference standards were also used, 
namely d4-glycocholic acid (d4-GCA) purchased from C/D/N Isotypes Inc. 
(Quebec,      Canada)      and      d4-taurocholic      acid      (d4-TCA),       d4- 
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glycochenodeoxycholic acid (d4-GCDCA), and d4-taurochenodeoxycholic 
acid (d4-TCDCA) from Toronto Research Chemicals Inc. (Ontario, Canada). 
All bile acid 3-sulfates were synthesized in our laboratory by the procedures 
reported in previous papers [16], as were the glycine- and taurine-conjugates, 
7α-hydroxy-3-oxo-4-cholenoic acid and 7α,12α-dihydroxy-3-oxo-4- 
cholenoic acid [17], and 5-cholenoic acids 3-sulfates, 3β-hydroxy-5- 
cholenoic acid, 3β,7α-dihydroxy-5-cholenoic acid, and 3β,7α,12α- 
trihydroxy-5-cholenoic acid [18,19]. In addition, we synthesized 7β-N- 
acetylglucosaminyl-UDCA (UDCA-7NAG), GUDCA-7NAG, 7β-N- 
acetylglucosaminyl-UDCA N-(2-sulfoethyl)amide(TUDCA-7NAG), 3α- 
sulfooxy-7β-N-acetylglucosaminyl-UDCA (UDCA-3S-7NAG), 3α- 
sulfooxy-7β-N-acetylglucosaminyl-UDCA N-(carboxymethyl)amide 
(GUDCA-3S-7NAG), and 3α-sulfooxy-7β-N-acetylglucosaminyl-UDCA 
N-(2-sulfoethyl)amide (TUDCA-3S-7NAG) [20,21]. Chemical structures of 
the unconjugated and conjugated ursodeoxycholic acids measured in this 
study are shown in Figure 1. 
All solvents and reagents used were analytical reagent grade and 
purchased from Kanto Chemical Co., Inc. (Tokyo, Japan). An InertSep C18- 
B (100 mg/1 ml) solid phase extraction cartridge was obtained from GL 
Sciences Inc. (Tokyo, Japan). 
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Preparation of standard solutions 
 
The individual stock solutions of bile acids were prepared separately at 5 
μmol/ml in ethanol and the stock solutions were stored at -20ºC. The 
individual stock solutions were mixed equally for analysis of unknown 
samples and five point-calibration standard solutions (30, 100, 300, 1000, 
3000 pmol/ml) for LC-ESI-MS/MS analysis were prepared in 20% 
acetonitrile. The calibration standard solutions were stable in analytical glass 
tubes for at least 2 weeks at 4ºC. 
 
 
Clinical samples 
 
Randomly collected urine samples were obtained from low birth weight 
(LBW) and normal birth weight (NBW) controls (UDCA non- 
administration) and patients who required UDCA for treatment of TPN- 
induced cholestasis. The age is shown as corrected gestational age (CGA), 
which is the gestational age plus the weeks after birth. In total, we analyzed 
samples from 8 controls of 36-44 weeks CGA (LBW; 3; 1198-1857g, NBW; 
5), 4 patients of 37-42 weeks CGA, 5 patients of 44-49 weeks CGA (LBW; 
4; 764-1980 g, NBW; 1), 4 patients of 55-70 weeks CGA (LBW; 4; 869- 
 
1637 g), 4 patients aged from 9 months to 3 years, and 4 patients aged 5-15 
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years. All the urine specimens were stored at -20ºC until use. The analysis 
values were standardized to creatinine excretion, being expressed as 
mmol/mol creatinine (mmol/molCr) in each specimen. The urinary 
creatinine levels were determined using the Jaffe method [22]. 
 
 
Sample preparation 
 
A 10-μl volume of deuterium-labeled internal standard, d4-CA, d4-GCA, 
d4-TCA, d4-GCDCA, and d4-TCDCA were mixed equally, and then added at 
100 nmol/ml each in 50% ethanol to 100 μl of sample. The solution was 
transferred onto the solid-phase extraction cartridge (InertSep C18-B 100 
mg/1 ml, pre-conditioned with 1 ml of methanol and 3 ml of H2O), which 
was washed with 1 ml of H2O and then eluted with 1 ml of 90% ethanol. 
After evaporation of the solvent, the residue was dissolved in 1 ml of 20% 
acetonitrile, and then 20 μl of the solution was injected into the LC-ESI- 
MS/MS. 
 
 
LC-ESI-MS/MS analysis 
 
The LC-ESI-MS/MS system comprised a TSQ Quantum Discovery Max 
mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) equipped 
with an ESI probe and Surveyor HPLC system (Thermo Fisher  Scientific). 
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A chromatography separation column, InertSustain C18 (150 mm × 2.1 mm 
ID, 3 μm particle size; GL Sciences Inc., Tokyo, Japan), was employed at 
35°C. A mixture of 10 mM ammonium acetate and acetonitrile was used as 
the eluent, and the separation carried out by linear gradient elution at a flow 
rate of 0.2 ml/min. The mobile phase composition was gradually changed as 
follows: ammonium acetate-acetonitrile (90:10, v/v) for 0.5 minutes, 
ammonium acetate-acetonitrile (78:22, v/v) for 0.5-5 minutes, ammonium 
acetate-acetonitrile (40:60, v/v) for 5-46 minutes, ammonium acetate- 
acetonitrile (2:98, v/v) for 46-56 minutes, and ammonium acetate- 
acetonitrile (2:98, v/v) for 4 minutes. The total run time was 60 minutes. 
To operate the LC-ESI-MS/MS, the spray voltage and vaporizer 
temperature were set at 3500 V and 330°C, respectively. The sheath and 
auxiliary gas (nitrogen) pressures were set at 50 and 10 arbitrary units, 
respectively, and the ion transfer capillary temperature was 330°C. The 
collision gas (argon) pressure and the collision energy were kept at 1.3 mm 
Torr and 27-55 eV, respectively, all in the negative ion mode [19,23]. 
 
 
Method validation 
 
The method was fully validated, in according to the ICH Q2(R1) [24]. 
Method   linearity  was   determined   by   analyzing   five point-calibration 
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standard solutions. Accuracy and precision were assessed using the three 
concentrations of urine samples spiked with known amount of bile acids, 
evaluated by analyzing five replicates per run of samples contained in one 
run per day over a 5-day period. LOD (limit of detection) was established 
using a method based on the calibration curves, LOD = 3.3σ/S (σ = the 
standard deviation of the response, S = the slope of the calibration curve used 
as deviation of y-intercept). Matrix effects were determined by comparing 
the linearity of working solutions prepared from extracted human urine 
samples to linearity in 20% acetonitrile. 
 
 
Results 
 
LC-ESI-MS/MS analysis of unconjugated and conjugated UDCA 
 
Using ESI-MS operating in the negative-ion mode, the related UDCA 
compounds analyzed herein possess a sulfooxy group at the 3 position, and 
a carboxyl group or amides conjugated with glycine or taurine at the 24 
position, terminal carbon atom of the side chain. LC-ESI-MS/MS analysis 
of UDCAs, UDCAs-3S, UDCAs-7NAG, and UDCAs-3S-7NAG were easily 
ionized by the electron spray ionization and fragmented under the condition 
of low-energy collision-induced dissociation (CID). The compounds’ 
precursor ions mainly formed from the deprotonated molecule [M−H]−      or 
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half of the 3-sulfate compounds formed doubly charged molecules [M−2H]2−. 
Those product ions were optimized at m/z 74 for glycine-conjugated bile 
acids, at m/z 124 for taurine-conjugate bile acids, and at m/z 97 for 3 variants 
of UDCAs-3S such as bile acid sulfates [19,23]. Whereas UDCAs-7NAG 
provided [UDCA]− at m/z 391.3, GUDCA-7NAG produced [NAG−H2O]− at 
m/z 202.1, TUDCA-7NAG gave [M−NAG]− at m/z 480.5, and GUDCA-3S- 
7NAG gave [M−SO3]− at m/z 651.6 (Table 1). Typical selected reaction 
monitoring (SRM) chromatograms for the authentic 12 variants of UDCA 
and related compounds, as shown in Figure 2, required 60 min for the 
simultaneous separation and determination of all bile acids. 
 
 
Linearity, sensitivity, and precision 
 
The linearity of the method was entered by 10 variants of conjugated 
UDCA standard curve calibrators ranging from 30 to 3000 pmol/ml. For the 
other acids, UDCA and GUDCA-7NAG, standard linearity ranged from 100 
to 30000 pmol/ml. Peak area ratios (analytes/internal standard) were 
proportional to the concentration. The calibration curves appeared linear and 
the slopes, the intercepts, and the correlation coefficients were determined 
by least square lines with a weighting factor of 1/(concentration)2. The 
correlation coefficients and detection limit LOD = 3.3σ/S (σ = the standard 
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deviation of the response, S = the slope of the calibration curve used as 
deviation of y-intercept) are listed in Table 2. 
To confirm the precision of UDCA-related quantification using LC-ESI- 
MS/MS, 5 replicates per run of samples and 1 run per day over a 5-day period 
were analyzed. Precision of compounds, measured as C.V. (%), ranged from 
0.6% to 12.9% and 3.3% to 25.9% for intraday and interday measurements, 
respectively (Table 3). 
 
Spiked urine samples were derived by adding individual derivative 
reagents to prepare the solution for recovery test. Five replicates at low and 
medium quality concentrations for 12 variants of UDCA-related bile acids 
were determined. Absolute recovery was determined to evaluate the 
measurement accuracy of the derivatives added to the three male urine 
samples in known quantities. Recoveries of UDCA-related bile acids from 
all urine samples are listed in Table 4. The results show no significant ion 
suppression or enhancement effects, nor were there significant matrix effects 
for other BAs. 
 
 
Application 
 
We analyzed 60 variant bile acids, usual bile acids non-amidated and 
amidated with glycine or taurine at their carboxylic group, with further 
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conjugation to sulfonic at the 3 position, in addition 3β-hydroxy-Δ5-bile 
acids unconjugated and conjugated with those and 3-oxo-Δ4-bile acids 
nonamidated and amidated with glycine or taurine at their carboxylic group. 
UDCAs-7NAG and UDCAs-3S-7NAG were newly determined in this study. 
Figure 3 shows the level of 60 variant BAs in 8 control samples, 13 urine 
samples obtained from patients including LBW and NBW being 
administered UDCA for TPN-related cholestasis from CGAs of 37 to 70 
weeks and 8 urine samples obtained from UDCA administration patients 
aged from 9 months to 15 years. The ratio of total UDCA to total BAs (TBA) 
in the control urines (n=8) from CGA 36-44 weeks was lower, 0.7%, whereas 
this ratio in urines from patients of CGA 37-42 weeks ranged from 26.5 to 
89.9%. Figure 4 compares UDCA-related BA composition in urines from 
individuals aged CGA 37-70 weeks to those aged 9 months to 15 year in 
patients treated with UDCA. The ratio to total UDCA at CGA 37-42 weeks 
were as follows; UDCAs: 44.0±8.0%, UDCAs-3S: 37.8 ± 10.1%,  UDCAs- 
7NAG: 18.1 ± 14.9%. And the ratio to total UDCA at 9months-3years were; 
UDCAs: 15.7 ± 23.2%, UDCAs-3S: 37.2 ± 8.8%, and UDCAs-7NAG: 47.0 
± 22.1%. Followed by UDCAs, the ratios of UDCAs conjugates by N- 
acethylglucosamine and sulfonic acid were close to adolescent UDCA 
components at 3 years. Of the 21 patients treated with UDCA, 2 did not 
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excrete UDCAs-7NAG, which may be considered as UDP- 
glycosyltransferase (UGT3A1) deficiency. UDCAs-3S-7NAG components 
were detected at levels lower than 0.2% at all ages. 
 
 
 
Discussion 
 
We describe here a simple, sensitive, and accuracy LC-ESI-MS/MS 
method for the determination of UDCA-7NAG, GUDCA-7NAG, TUDCA- 
7NAG, and their 3α-sulfonic acid double conjugates in urine. This method 
also analyzed another 54 BA variants such as usual BAs, 3-oxo-Δ4- BAs, 3β- 
hydroxy-Δ5-BAs, and those conjugated to glycine, taurine, and sulfonic acid 
simultaneously. We found that the MS/MS conditions of measurement for 
UDCAs-7NAG and UDCAs-3S-7NAG were different from those for other 
bile acids in collision fragments. The ordinary product ion (m/z) of 
conjugated BAs are for glycine conjugate: 74 [H2NCH2COO-], taurine 
conjugate: 124 [H2NC2H4SO3-], and sulfate: 97 [HSO4-], while those for each 
UDCA conjugate are UDCA-7NAG: 391.3, GUDCA-7NAG: 202.1, 
TUDCA-7NAG: 480.5, UDCA-3S-7NAG: 97.0, GUDCA-3S-7NAG: 651.6, 
and TUDCA-3S-7NAG: 96.9 [25,26]. 
 
While large amounts of UDCAs-7NAG in the urine and serum of PBC 
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patients treated with UDCA indicates disease progression [9], the 
physiological significance of BA N-acetylglucosaminide is not clear, 
although it might be a metabolite of conversion into a form capable of 
urinary excretion or of sulfated BA formation. HPLC methods have been 
used to analyze UDCAs-7NAG concentrations in adult urine and serum, 
including fluorescence labeled treatment, GC/MS method using 
trimethylsilylether derivatization, and immunoassay using diluted sample 
specimen, but not LC-ESI-MS/MS. In addition the levels of UDCAs-7NAG 
in neonates or infants have not been analyzed by any method. BA N- 
acetylglucosamination might be considered to occur as UGT3A1, mainly in 
the kidney, while sulfation activity is present in both liver and kidney, and 
the activity is increased relatively early in the neonatal period. These results 
describe the transition of UDCA-7β-N-acetylglucosaminide and 3α-sulfate 
urine concentrations from neonates including LBW to adolescents receiving 
UDCA using LC-ESI-MS/MS analysis. General enzymes involved in drug 
metabolism are those of the cytochrome P450 (CYP) family (phase I 
reactions) and the uridine diphosphate glucuronosyltransferase (UGT), 
sulfotransferase, glutathione-S-transferase, and N-acetyltransferase families 
(phase II reactions). There are also specific isozymes within each family that 
mature at different rates during the first several years of life. The effect   on 
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metabolism of a specific medication thus depends on the dominant 
enzymatic pathways responsible for metabolism of the drug [27,28]. Herein, 
we compared the level of sulfate conjugation at C-3α-OH and N- 
acetylglucosaminidation at C-7β-OH to UDCA to metabolites of UDCA in 
neonatal urine from patients treated with UDCA, and found that there are 
activities of both N-acetylglucosaminidation to UDCA and sulfate 
conjugation, already existing in the early neonatal period (CGA 37-42w). 
This expression gradually increases in the first 1–2 years after birth and 
stabilizes at 3–5 years. The urinary concentration ratios of GUDCA-3S and 
GUDCA-7NAG to total UDCA are about 40% respectively, which could be 
related to the maturation of this pathway after UDCA administration in the 
neonate age groups compared to the adolescents group. Sulfate or glycine 
conjugation of general drug metabolism appears to be very efficient at birth 
[27,28], while the maturation of sulfation to UDCA was not likely to be 
earlier than N-acethylglucosaminidation. The UGT3A1 deficiency is 
reported as about 10% in the study of the Niemann Pick Type C biomarker 
analyzing 3α-sulfooxy-7β-N-acethylglucosaminyl-Δ5-cholen-24-oic acid 
[29], and similarly in this study, 2 of 21 samples showed no UDCAs-7NAG. 
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Legends for figures 
 
 
 
Fig. 1. Chemical structures of the unconjugated and conjugated 
ursodeoxycholic acids measured in this study. 
 
 
Fig. 2. SRM chromatograms of unconjugated and conjugated UDCA. 
 
 
 
Fig. 3. The concentration of total UDCA and other bile acids in urine samples 
from controls and patients administered with UDCA treatment. The error 
bars show mean + SD measured total bile acids. 
 
 
Fig. 4. Bile acid composition of unconjugated and conjugated UDCA in urine 
samples with patients administered with UDCA treatment. 
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Table 1 LC-ESI-MS/MS parameters of reference bile acids 
Bile acid Exact mass 
Precursor ion Product ion CE R.T. 
I.S. 
(m/z ) (m/z ) (eV) (min) 
UDCA 392.3 391.3 373.2 32 40.2 d 4-CA 
GUDCA 449.3 448.3 74.1 42 25.3 d 4-GCA 
TUDCA 499.3 498.3 124.0 51 27.0 d 4-TCA 
UDCA-3S 472.2 471.3 97.0 55 28.1 d 4-TCA 
GUDCA-3S 529.3 263.7 97.0 40 13.6 d 4-GCA 
TUDCA-3S 579.2 288.7 97.0 39 14.1 d 4-TCA 
UDCA-7NAG 595.4 594.3 391.3 37 29.3 d 4-CA 
GUDCA-7NAG 652.4 651.4 202.1 42 18.1 d 4-GCA 
TUDCA-7NAG 702.4 701.4 480.5 59 19.4 d 4-TCA 
UDCA-3S-7NAG 675.4 674.4 97.0 56 20.6 d 4-TCA 
GUDCA-3S-7NAG 732.4 731.4 651.6 38 11.9 d 4-GCA 
TUDCA-3S-7NAG 782.3 390.3 96.9 40 12.4 d 4-TCA 
  
 
 
Table 2 Linearity and sensitivity by LC-ESI-MS/MS 
  R2 LOD (pmol/ml) 
UDCA Y = -0.0390837 + 0.00151159*X 0.9820 14.9 
GUDCA Y = -0.0217101 + 0.00784317*X 0.9986 1.4 
TUDCA Y = -0.036625 + 0.0104595*X 0.9935 2.6 
UDCA-3S Y = -0.0290815 + 0.0202048*X 0.9935 0.3 
GUDCA-3S Y = -0.0680329 + 0.0104239*X 0.9881 3.2 
TUDCA-3S Y = -0.124764 + 0.0171295*X 0.9904 0.7 
UDCA-7NAG Y = -0.0779121 + 0.0414377*X 0.9838 0.7 
GUDCA-7NAG Y = -0.00349256 + 0.000662858*X 0.9298 16.9 
TUDCA-7NAG Y = -0.0237714 + 0.0239131*X 0.9865 0.5 
UDCA-3S-7NAG Y = -0.0164075 + 0.0054547*X 0.9942 1.2 
GUDCA-3S-7NAG Y = -0.965213 + 0.134727*X 0.9825 0.2 
TUDCA-3S-7NAG Y = -0.0142812 + 0.00452874*X 0.9976 2.5 
  
 
 
Table 3 intra-day (n-5) and inter-day (n=5) 
Bile acid    Intra-day (n=5)       Inter-day (n=5)    
mean  SD mean  SD mean  SD mean  SD mean  SD mean  SD 
 97.8 ± 5.5 485.7 ± 14.5 1928.7 ± 27.1 108.8 ± 12.8 552.2 ± 25.2 1974.5 ± 131.5 
TUDCA 99.2 ± 9.6 491.5 ± 28.8 2025.8 ± 38.5 109.0 ± 20.1 516.5 ± 30.2 2001.0 ± 155.1 
UDCA 94.2 ± 1.8 484.4 ± 4.7 1987.6 ± 13.2 109.9 ± 15.8 502.9 ± 19.9 1991.6 ± 98.5 
GUDCA3S 94.8 ± 0.9 477.9 ± 21.5 1885.4 ± 29.1 101.0 ± 14.5 495.5 ± 47.0 1902.2 ± 49.8 
TUDCA3S 94.4 ± 4.0 493.6 ± 7.3 1869.9 ± 25.0 100.6 ± 5.1 516.9 ± 17.0 2007.2 ± 59.8 
UDCA3S 95.3 ± 3.1 493.5 ± 9.3 1958.8 ± 13.7 102.4 ± 9.8 490.9 ± 34.1 1988.7 ± 78.3 
GUDCA-7NAG 93.0 ± 12.9 492.8 ± 30.9 2035.0 ± 45.7 91.0 ± 23.5 486.5 ± 43.1 1950.9 ± 105.2 
TUDCA-7NAG 103.0 ± 3.3 515.4 ± 14.5 2022.6 ± 29.3 113.0 ± 7.7 564.9 ± 97.3 2012.7 ± 67.6 
UDCA-7NAG 102.8 ± 0.6 520.2 ± 6.3 2102.9 ± 56.4 99.9 ± 7.8 506.4 ± 39.9 2012.7 ± 65.6 
GUDCA-3S-7NAG 94.5 ± 1.6 472.9 ± 7.7 1862.4 ± 21.7 103.5 ± 7.5 498.3 ± 60.1 1969.8 ± 95.5 
TUDCA-3S-7NAG 94.1 ± 3.6 476.8 ± 12.0 1881.7 ± 44.2 103.3 ± 10.5 488.6 ± 36.3 1984.9 ± 55.1 
UDCA-3S-7NAG 96.3 ± 7.1 504.1 ± 10.2 2071.7 ± 19.6 103.9 ± 7.0 498.1 ± 33.0 2013.4 ± 69.5 
  
 
 
Table 4 Relative recoveries of unconjugated and conjugated ursodeoxycholic acids from urine. 
Bile acid Concentration added 100 pmol/ml Concentration added 500 pmol/ml Concentration added 2000 pmol/ml recovery (%, mean ± SD) recovery (%, mean ± SD) recovery (%, mean ± SD) 
GUDCA 97.8 ± 5.5 97.1 ± 2.8 96.4 ± 1.3 
TUDCA 99.2 ± 9.6 98.3 ± 5.7 101.3 ± 1.9 
UDCA 94.2 ± 1.8 96.9 ± 0.9 99.4 ± 0.7 
GUDCA3S 94.8 ± 0.9 95.6 ± 4.1 94.3 ± 1.4 
TUDCA3S 94.4 ± 4.0 98.7 ± 1.4 93.5 ± 1.2 
UDCA3S 95.3 ± 3.1 98.7 ± 1.8 97.9 ± 0.7 
GUDCA-7NAG 93.0 ± 12.9 98.6 ± 6.1 101.7 ± 2.3 
TUDCA-7NAG 103.0 ± 3.3 103.1 ± 3.0 101.1 ± 1.5 
UDCA-7NAG 102.8 ± 0.6 104.0 ± 1.3 105.1 ± 3.0 
GUDCA-3S-7NAG 94.5 ± 1.6 94.6 ± 1.5 93.1 ± 1.0 
TUDCA-3S-7NAG 94.1 ± 3.6 95.4 ± 2.3 94.1 ± 2.1 
UDCA-3S-7NAG 96.3 ± 7.1 100.8 ± 2.1 103.6 ± 1.0 
 
